Adam Kirby

This study evaluates the pharmacokinetics, biodistribution, and therapeutic efficacy of a trimeric nanobody against SARS-CoV-2 in golden Syrian hamsters, showing that intranasal administration provides effective respiratory exposure and therapeutic benefit.

This study investigates the biodistribution and effects of Ronapreve in a mouse model of SARS-CoV-2 infection, showing it does not reach the brain but reduces viral loads in the lung and brain.

This study shows that HIF activation limits pneumovirus replication by enhancing innate immune sensing and reducing viral RNA methylation.

This study identifies two potent nanobodies targeting the conserved S2 region of SARS-CoV-2 spike protein that resist viral escape and reduce viral load in a hamster model.

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.

This study examines how molnupiravir and nirmatrelvir affect SARS-CoV-2 genome diversity in immunocompromised mice, finding reduced viral load and specific mutations but no major consensus sequence changes.

This study re-establishes the golden Syrian hamster as an MCF model and identifies T cells and macrophages as key infected cells, with broader viral tropism including endothelial cells and epithelia.

This study uses a K18-hACE2 mouse model to show SARS-CoV-2 infects neurons in the brain without damaging blood vessels, leading to limited neuroinflammation.

This study identifies two bovine-derived monoclonal antibodies with ultra-long CDRH3 domains that broadly neutralize SARS-CoV-2 and sarbecoviruses.

This study shows that hypoxia inducible factors (HIFs) suppress RSV infection by reducing nucleolin expression and inhibiting viral replication and inflammation.